

Tamiflu®/ Relenza® and Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency

| Oseltamivir | Possible use after analysis of data available (literature and pharmacovigilance) |
|-------------|--|
|-------------|--|

Special recommendations for the attention of healthcare professionals

This medicine may be taken.

Instructions for the attention of patients with G6PD deficiency

This medicine may be taken.

Additional information

To date, no haemolytic risk has been identified in subjects with G6PD deficiency for oseltamivir.

Proprietary medicinal products

- TAMIFLU[®] 12mg/mL, powder for oral suspension
 TAMIFLU[®] 45mg, capsule
 TAMIFLU[®] 75mg, capsule
- TAMIFLU®30mg, capsule

| Zanamivir | Possible use after analysis of data available (literature and pharmacovigilance) |
|-----------|--|
|-----------|--|

Special recommendations for the attention of healthcare professionals

This medicine may be taken.

Instructions for the attention of patients with G6PD deficiency

This medicine may be taken.

Additional information

To date, no haemolytic risk has been identified in subjects with G6PD deficiency for zanamivir.

Proprietary medicinal products

RELENZA[®] 5mg per dose, powder for inhalation in single dose container